CytomX Therapeutics, Inc. (CTMX) reported a net loss of $20.4 million or $0.15 per share for fiscal 2025, compared to a profit of $31.9 million or $0.38 per share last year. Full-year revenues declined to $76.2 million from $138.1 million in fiscal 2024.
As of December 31, 2025, cash equivalents and investments totaled $137.1 million, compared to $100.6 million last year. Shares of the company traded at $4.87. on volume of 2,864,938. The company has a market capitalization of $1.32 billion.
A detailed analysis of CytomX Therapeutics, Inc.’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.